Phoenix, AZ, June 18, 2010 – VisionGate has been officially awarded a three-year, $2.62 million grant from NIH as part of an initiative called Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Program. The program is designed to provide funding for accelerating the market introduction of breakthrough technologies that “…will improve human health, help advance the mission of NIH and its Institutes and Centers (ICs), and create significant value and economic stimulus.” The peer-reviewed selection process for this program has been highly competitive: nationwide, only ten companies were elected to participate. The grant will be used to complete the development of VisionGate’s high-speed/high-throughput Cell-CT, a 3D-imaging platform with diagnostic applications in lung cancer and other important diseases.
Additionally, VisionGate has been awarded two grants through NIH’s Small Business Innovation Research (SBIR) program. Phase I of each grant is supported with approximately $200k, while substantially larger funds will be available when the projects enter Phase II.
Principal Investigator of the three grants is Thomas Neumann, MD, Vice President for Medical Sciences at VisionGate.